Jagsonpal Pharmaceuticals Ltd - 507789 - Clarification sought from Jagsonpal Pharmaceuticals Ltd
The Exchange has sought clarification from Jagsonpal Pharmaceuticals Ltd on July 12, 2021, with reference to Movement in Volume.The reply is awaited. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window
Closure of trading window. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board recommends Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 30, 2021, inter alia, has recommended dividend @ 20% per Equity Shares of face value of Rs. 5/- each, i.e. Re. 1/- per Equity Share. Jagsonpal Pharmaceuticals Ltd - 507789 - Outcome Of The Board Meeting
Outcome of the Board Meeting Jagsonpal Pharmaceuticals Ltd - 507789 - Audited Financial Results For The Quarter And Year Ended 31.03.2021.
OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON JUNE 30TH, 2021. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board to consider Dividend
Jagsonpal Pharmaceuticals Ltd has informed BSE that a Meeting of Board of Directors of the Company will be held on June 30, 2021, inter alia, to consider and approve the following business:1. To consider and approve the Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2021 along with half yearly Statement of Assets & Liabilities;2. To consider and take on record the Statutory Auditor's Report on Standalone Audited Financia! Results of the Company for the year ended March 31, 2021;3. To consider Dividend, if any;4. To approve the notice of 42nd Annual General Meeting;5. To approve Draft Director's Report together with other relevant reports;6. To consider and approve the E-Voting facility fram NSDL;7. To fix the Book Closure date and cut-off date for the purpose of Annual General Meeting;8. To appoint Scrutinizer for conducting E-voting. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Audited Financial Results For The Quarter And Financial Year Ended March 31, 2021
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2021 ,inter alia, to consider and approve 1. To consider and approve the Standalone Audited Financial Results of the Company for the quarter and year ended 31st March, 2021 along with half yearly Statement of Assets & Liabilities; 2. To consider and take on record the Statutory Auditor's Report on Standalone Audited Financial Results of the Company for the year ended 31st March, 2021; 3. To consider Dividend, if any; 4. To approve the notice of 42nd Annual General Meeting; 5. To approve Draft Director's Report together with other relevant reports; 6. To consider and approve the E- Voting facility from NSDL; 7. To fix the Book Closure date and cut-off date for the purpose of Annual General Meeting; 8. To appoint Scrutinizer for conducting E-voting; 9. Any other matters; Jagsonpal Pharmaceuticals Ltd - 507789 - Clarification On Price Movement.
Clarification on Price Movement. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Clarification sought from Jagsonpal Pharmaceuticals Ltd
The Exchange has sought clarification from Jagsonpal Pharmaceuticals Ltd on June 07, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. Jagsonpal Pharmaceuticals Ltd - 507789 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24 A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1//27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2021